Course Curriculum

Led by ATMA, a pioneer in legal psychedelic-assisted therapy in Canada, the program offers 126 lessons and 14.5 hours of video content, equipping medical professionals with the knowledge and skills to integrate psychedelic therapies into their practice. Discover a new frontier in healing and personal growth.

    1. Welcome!

    2. Mark Haden

    3. Dr. Devon Christie

    4. Bruce Sanguin

    5. Saundra Jain

    6. Dr. Rakesh Jain

    7. Dr. Anthony Bossis

    8. Kim Haxton

    9. Dr. Ben Malcolm

    10. Alex Belser

    11. Dr. Pam Kryskow

    12. Zach Walsh

    13. Dr. Ravinder Bains

    14. Dr. Monika Hooper

    1. M1 Overview: Psychedelics are Medicine - Mark Haden

    2. M1 Overview: The Categories of Psychedelics - Mark Haden

    3. M1 Overview: Psychedelics - Nature vs Lab - Dr. Rakesh Jain

    4. M1 Overview: Are manmade compounds missing out on the full spectrum of what nature can provide? - Dr. Rakesh Jain

    5. M1 Overview: The Benefits of the Psychedelic Experience - Alex Belser

    6. M1 Overview: Psychedelics and the Prescriber - Monika Hooper

    7. M1 Overview: Psychedelics in the Context of Holistic Psychiatric Care - Monika Hooper

    8. M1 History: History Of Psychedelics - Mark Haden

    9. M1: History: Untold History Of Psychedelics - Mark Haden

    10. M1 Current Study and Research of Psychedelics: Section 56 Exemptions, SAP and Trials-Accessing Psychedelics - Mark Haden

    11. M1 Current Study and Research of Psychedelics: Microdosing Psychedelics - Zach Walsh

    12. M1 BONUS MATERIAL: Current Study and Research of Psychedelics: Microdosing Survey Outcomes - Zach Walsh

    13. M1 Current Study and Research of Psychedelics: Psychedelics and Wellness Study 2019 - Saundra Jain

    1. M2 The Psychedelic Medicines-Types and Descriptions: Psilocybin - Mark Haden

    2. M2 The Psychedelic Medicines-Types and Descriptions: MDMA - Mark Haden

    3. M2 The Psychedelic Medicines-Types and Descriptions: MDMA and Psilocybin-Clinical Indications - Alex Belser

    4. M2 The Psychedelic Medicines-Types and Descriptions: DMT and 5-MeO-DMT - Mark Haden

    5. M2 BONUS MATERIAL: The Psychedelic Medicines-Types and Descriptions: 2C-B - Mark Haden

    6. M2 BONUS MATERIAL: The Psychedelic Medicines-Types and Descriptions: 3-MMC - Mark Haden

    7. M2 The Psychedelic Medicines-Types and Descriptions: LSD - Mark Haden

    8. M2 BONUS MATERIAL: The Psychedelic Medicines-Types and Descriptions : MEAI - Mark Haden

    9. M2 The Psychedelic Medicines-Types and Descriptions: Ketamine - Uses and Benefits - Rakesh Jain

    10. M2 The Psychedelic Medicines-Types and Descriptions: Maximizing The Benefits in Ketamine Application - Dr. Rakesh Jain

    11. M2 The Psychedelic Medicines-Types and Descriptions: Psychedelics And The Four Neurotransmitters - Dr Rakesh Jain

    12. M2 The Psychedelic Medicines-Types and Descriptions: Comparing Effects and Outcomes of Psilocybin, MDMA and Ketamine Therapy - Zach Walsh

    13. M2 The Psychedelic Medicines-Neurobiology: Pharmacology in Relation to Psychedelics - Ben Malcolm

    14. M2 The Psychedelic Medicines-Neurobiology: Neurobiology and Effects of Psychedelics - Ben Malcolm

    15. M2 The Psychedelic Medicines-Neurobiology: Leading Theories in Neurobiology for Psychedelics - Ben Malcolm

    16. M2 The Psychedelic Medicines-Neurobiology: Overview of MDMA - Ben Malcolm

    17. M2 The Psychedelic Medicines-Neurobiology: MDMA Side Effects - Ben Malcolm

    18. M2 The Psychedelic Medicines-Neurobiology: MDMA Pharmacodynamics - Ben Malcolm

    19. M2 The Psychedelic Medicines-Neurobiology: MDMA Pharmacokinetics - Ben Malcolm

    20. M2 The Psychedelic Medicines-Neurobiology : MDMA Drug Interactions - Ben Malcolm

    21. M2 The Psychedelic Medicines-Neurobiology: Seratonin Syndrome/Toxicity - Ben Malcolm

    22. M2 The Psychedelic Medicines-Neurobiology: Overview of Psilocybin - Ben Malcolm

    23. M2 The Psychedelic Medicines-Neurobiology: Psilocybin Pharmacodynamics and Pharmacokinetics - Ben Malcolm

    24. M2 The Psychedelic Medicines-Neurobiology: Psilocybin Drug Interactions - Ben Malcolm

    25. M2 The Psychedelic Medicines-Neurobiology: Ketamine Overview - Ben Malcolm

    26. M2 The Psychedelic Medicines-Neurobiology: Ketamine Pharmacodynamics - Ben Malcolm

    27. M2 The Psychedelic Medicines-Neurobiology: Ketamine Pharmacokinetics - Ben Malcolm

    28. M2 The Psychedelic Medicines-Neurobiology : Ketamine Drug Interactions - Ben Malcolm

    29. M2 The Psychedelic Medicines-Neurobiology: Final Thoughts-The Data Will Set Us Free - Ben Malcolm

    1. M3 Access and Inclusivity: Indigenous Perspectives - Benefits of Medicine Circles and Individual Ceremonies - Kim Haxton

    2. M3 Access and Inclusivity: Indigenous Perspectives - Bridging The Gap With Psychedelics - Kim Haxton

    3. M3 Access and Inclusivity: Indigenous Perspectives - Indigenous-Informed Ways to Offer Psychedelics to Diverse Populations - Kim Haxton

    4. M3 Access and Inclusivity: Indigenous Perspectives - Settler Reflexivity - Kim Haxton

    5. M3 Access for Diverse and Under-privileged Populations: Making a difference in First Nations Communities - Kim Haxton

    6. M3 Access for Diverse and Under-privileged Populations: Challenges of Access for Diverse Populations - Kim Haxton

    7. M3 Access for Diverse and Under-privileged Populations: Reciprocity - Kim Haxton

    8. M3 Access for Diverse and Under-privileged Populations: The Future of Accessibility - Alex Belser

    9. M3 Access for Diverse and Under-privileged Populations: The Challenge of Accessibility to Psychedelic Treatments - Monika Hooper

    10. M3 Access for Diverse and Under-privileged Populations: The Special Access Program (SAP) Process for Psilicybin and MDMA - Monika Hooper

    11. M3 Cultural Considerations: Cross Cultural Considerations - Kim Haxton

    12. M3 Cultural Considerations: What We Need To Know About Psychedelics, LGBTQIA+ and BIPOC - Alex Belser

    1. M4 The Therapeutic Facilitator: The Role of a Prescriber in Referring to a PaT Facilitator - Rakesh Jain

    2. M4 Basic Principles of Guiding/Sitting: - The Value Of Working Within A Team Of Psychedelic Therapists - Pam Kryskow

    3. M4 Basic Principles of Guiding/Sitting: A Pragmatic Approach to Trauma-Informed Psychedelic Work - Rakesh Jain

    4. M4 Self-Care for the Facilitator: Therapist Support Networks for Self-Care - Saundra Jain

    1. M5 Codes of Ethics for Psychedelic-Assisted Therapy: Where To Go For Ethical Guidelines - Saundra Jain

    2. M5 Codes of Ethics for Psychedelic-Assisted Therapy: The Importance Of Creating A Code Of Ethics For PaT - Devon Christie

    3. M5 Codes of Ethics for Psychedelic-Assisted Therapy: How The 4 Pillars Of Healthcare Ethics Should Inform PaT - Devon Christie

    4. M5 Codes of Ethics for Psychedelic-Assisted Therapy: The Ethical Psychedelic Practitioner - Pam Kryskow

    5. M5 Consent/Boundaries and Appropriate Touch: Informed Consent In Psychedelic Treatment - Devon Christie

    6. M5 Consent/Boundaries and Appropriate Touch: When Touch Is Important And Useful - Devon Christie

    7. M5 Consent/Boundaries and Appropriate Touch: Navigating Touch Options for PaT - Devon Christie

    8. M5 Harm Reduction - Challenging Situations and Adverse Effects: When Should Harm Reduction Begin? - Rakesh Jain

    9. M5 Harm Reduction - Challenging Situations and Adverse Effects: Harm Reduction Principles - Saundra Jain

    10. Module 5 Additional Downloadable Resources

Course Highlights

  • $1,897.00
  • 126 lessons
  • 14.5 hours of video content

Instructor(s)

ATMA Training

ATMA is a Canadian company focused on delivering effective and innovative healing and transformative experiences that leverage the potential of psychedelic medicine to awaken the inner healer and allow a deeper connection with self, with others and with the beauty of our world.  ATMA was the first private company in Canada to conduct legal psychedelic-assisted therapy with psilocybin, one of the active hallucinogens found in ‘magic mushrooms’.